Jefferies Financial Group Inc. Takes Position in Xencor, Inc. $XNCR

Jefferies Financial Group Inc. bought a new position in Xencor, Inc. (NASDAQ:XNCR) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 720,440 shares of the biopharmaceutical company’s stock, valued at approximately $11,599,000. Jefferies Financial Group Inc. owned about 0.97% of Xencor as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of XNCR. Tower Research Capital LLC TRC lifted its holdings in Xencor by 118.4% in the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares during the period. Allworth Financial LP acquired a new stake in shares of Xencor during the 2nd quarter worth approximately $55,000. E Fund Management Co. Ltd. purchased a new position in shares of Xencor during the 2nd quarter valued at approximately $79,000. iSAM Funds UK Ltd purchased a new position in shares of Xencor during the 2nd quarter valued at approximately $122,000. Finally, Prelude Capital Management LLC acquired a new position in shares of Xencor in the 3rd quarter valued at $139,000.

Xencor Price Performance

Shares of NASDAQ:XNCR opened at $28.88 on Friday. The business’s 50 day moving average price is $19.54 and its 200-day moving average price is $14.69. Xencor, Inc. has a 1 year low of $7.83 and a 1 year high of $30.61. The firm has a market capitalization of $2.15 billion, a price-to-earnings ratio of -13.31 and a beta of 0.85.

Xencor (NASDAQ:XNCR) last issued its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. The company had revenue of $51.22 million during the quarter, compared to analyst estimates of $18.89 million. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The firm’s revenue was up 17.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.41) EPS. On average, sell-side analysts expect that Xencor, Inc. will post -3 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the stock. Wall Street Zen raised shares of Xencor from a “strong sell” rating to a “hold” rating in a report on Saturday, August 8th. Zacks Research upgraded shares of Xencor from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Truist Financial lowered their target price on shares of Xencor from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Tuesday, July 7th. JPMorgan Chase & Co. raised their target price on Xencor from $13.00 to $14.00 and gave the company a “neutral” rating in a research report on Monday, May 11th. Finally, Cantor Fitzgerald lifted their price target on Xencor from $43.00 to $44.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Five analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $24.86.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.